📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-07 12:10
0 analysed today
FollowTelegram
0
Today
151,433
All-time analysed
43,376
Positive
6,732
Negative
92,513
Neutral
8,744
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
3 announcements match the current filters (relevance ≥ 5).
Makers Labs: CEO Saahil Parikh transitions to Non-Executive role; Q1 Cons. PAT at Rs 1.09 Cr
Makers Laboratories has announced that Mr. Saahil Parikh will step down as Whole-time Director and CEO effective August 10, 2026, transitioning to a Non-Executive, Non-Independent Director role. For the quarter ended June 30, 2026, the company reported consolidated revenue of Rs 42.77 Cr, a 22.2% increase from Rs 35.00 Cr in the previous year's corresponding quarter. Consolidated net profit rose to Rs 1.09 Cr from Rs 0.44 Cr YoY. However, the standalone business remains under pressure, reporting a net loss of Rs 0.27 Cr for the quarter.
Confidence: HIGH
What changedThe CEO is stepping down from executive responsibilities to a non-executive board role, and the company reported its Q1 FY27 financial results showing consolidated growth but standalone losses.
Why it mattersLeadership changes in small-cap companies (Market Cap Rs 322 Cr) are significant for operational continuity; however, the outgoing CEO's retention on the board suggests a stable transition.
Consolidated Revenue (Q1 FY27): Rs 42.77 CrConsolidated Net Profit (Q1 FY27): Rs 1.09 CrStandalone Net Loss (Q1 FY27): Rs 0.27 CrCEO Transition Date: August 11, 2026Consolidated Revenue Growth (YoY): 22.2%
📅 Short termThe stock may see neutral to slightly volatile movement as the market digests the CEO transition alongside mixed earnings results (consolidated profit vs standalone loss).
📈 Long termThe long-term outlook depends on the new executive leadership's ability to scale the pharmaceutical business and improve the current 10.5% operating margins.
⚠ Risk flags
- Leadership transition risk
- Persistent standalone net losses
- Small-cap liquidity and volatility
Key Highlights
Mr. Saahil Parikh transitions from CEO/Whole-time Director to Non-Executive Director effective August 11, 2026
Consolidated Revenue for Q1 FY27 increased to Rs 42.77 Cr from Rs 35.00 Cr YoY
Consolidated Net Profit for the quarter improved to Rs 1.09 Cr compared to Rs 0.44 Cr in Q1 FY26
Standalone operations reported a net loss of Rs 0.27 Cr on revenue of Rs 13.73 Cr
Mr. Nilesh Jain remains as the sole Executive Whole-time Director following the board reconstitution
👀 What to Watch
Investors should monitor the leadership transition to Mr. Nilesh Jain and observe if the company can improve standalone profitability, which currently lags behind consolidated performance.
Makers Labs Q1: Consolidated PAT jumps 150% to ₹1.09 Cr; CEO Saahil Parikh to step down
Makers Laboratories reported a strong consolidated performance for Q1 FY27, with revenue growing 22.2% YoY to ₹42.77 Cr. Consolidated Net Profit attributable to owners surged 150% to ₹1.09 Cr, up from ₹0.44 Cr in the previous year's quarter. However, standalone operations remain a concern, posting a net loss of ₹1.08 Cr. The company also announced that CEO Saahil Parikh will transition to a Non-Executive Director role effective August 11, 2026, following the end of his current term.
Confidence: HIGH
What changedThe company saw a significant jump in consolidated profitability while simultaneously announcing a transition in its top leadership as the CEO moves to a non-executive role.
Why it mattersThe results highlight that the company's value is increasingly tied to its consolidated entities, as the standalone parent company continues to operate at a loss. The leadership change is a key event for a small-cap firm.
Consolidated Revenue (Q1): ₹42.77 CrConsolidated PAT (Q1): ₹1.09 CrStandalone Net Loss (Q1): ₹1.08 CrConsolidated Revenue vs TTM Revenue: 30.3%CEO Transition Date: 11th August 2026
📅 Short termThe stock may see positive momentum due to the sharp rise in consolidated profits, though the CEO's departure from executive roles may temper enthusiasm.
📈 Long termLong-term sustainability depends on turning around the standalone operations and ensuring a smooth leadership transition to maintain the growth seen in subsidiaries.
⚠ Risk flags
- Standalone loss-making operations
- CEO transition/succession risk
- High P/E ratio of 40.9 relative to small-cap size
Key Highlights
Consolidated Revenue from Operations increased 22.2% YoY to ₹42.77 Cr from ₹35.00 Cr.
Consolidated Net Profit (attributable to owners) rose 150% to ₹1.09 Cr compared to ₹0.44 Cr in Q1 FY26.
Standalone operations reported a net loss of ₹1.08 Cr, slightly higher than the ₹0.96 Cr loss in the year-ago period.
CEO Saahil Parikh to step down from executive duties on August 10, 2026, remaining as a Non-Executive Director.
Consolidated EPS improved to ₹1.85 from ₹0.74 YoY.
👀 What to Watch
Investors should monitor the appointment of a new CEO and track whether the consolidated subsidiaries can maintain their growth to offset the persistent losses in the standalone business.
Rs 42.77 Cr Q1 Revenue; CEO Saahil Parikh Transitions to Non-Executive Role
Makers Laboratories reported a consolidated revenue of Rs 42.77 Cr for Q1 FY27, representing a 22.2% increase compared to Rs 35.00 Cr in the same quarter last year. Net profit attributable to owners rose to Rs 1.09 Cr from Rs 0.44 Cr YoY, though it declined sequentially from Rs 1.50 Cr in March 2026. A significant divergence persists between consolidated and standalone performance, with the standalone entity reporting a net loss of Rs 1.72 Cr. Additionally, CEO Saahil Parikh will transition to a Non-Executive Director role effective August 11, 2026, upon the completion of his current term.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results and announced that its CEO, Saahil Parikh, will step down from his executive role to become a Non-Executive Director.
Why it mattersThe strong consolidated top-line growth (30% of TTM revenue in one quarter) is a positive signal, but the standalone loss and management transition at the CEO level introduce elements of uncertainty regarding operational execution.
Consolidated Revenue (Q1 FY27): Rs 42.77 CrConsolidated PAT (Owners' Share): Rs 1.09 CrStandalone Net Loss: Rs 1.72 CrQ1 Revenue vs TTM Revenue: 30.33%Consolidated EPS (Basic): Rs 1.85
📅 Short termThe stock may see mixed reactions as the market weighs strong consolidated revenue growth against a standalone loss and the transition of the CEO to a non-executive role.
📈 Long termThe long-term outlook depends on the company's ability to stabilize standalone operations and the effectiveness of the leadership transition in maintaining the current growth trajectory of its subsidiaries.
⚠ Risk flags
- Standalone business is loss-making
- Key management transition (CEO)
- High P/E ratio of 40.9 relative to modest PAT
Key Highlights
Consolidated Revenue from Operations grew 22.2% YoY to Rs 42.77 Cr.
Net Profit attributable to owners increased to Rs 1.09 Cr from Rs 0.44 Cr in the year-ago period.
Standalone operations reported a net loss of Rs 1.72 Cr for the quarter ended June 30, 2026.
CEO Saahil Parikh transitions to a Non-Executive, Non-Independent Director role effective August 11, 2026.
Consolidated Total Income for the quarter stood at Rs 43.38 Cr compared to Rs 35.27 Cr YoY.
👀 What to Watch
Investors should monitor the performance of the company's subsidiaries, which are currently driving consolidated profitability, while the standalone business remains loss-making. Watch for the appointment of a new CEO to lead executive operations.
